CAPR plunged ~64% after FDA briefing docs hit

Deramiocel AdCom is Wednesday. Capricor says staff leaned on an obsolete SAP. Plus this week's free new-to-stocks report. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  

July 28, 2026 CAPR Plunged About 64% After FDA Staff Briefing Docs Hit Capricor Therapeutics (CAPR) closed near $7.00 on Monday after opening the session near $19.50. That is roughly a 64% one-day collapse on more than 29 million shares. The spark was not a surprise trial flop. It was FDA staff briefing materials ahead of Wednesday's advisory committee on Deramiocel for Duchenne muscular dystrophy cardiomyopathy. Capricor fired back the same morning. CEO Linda Marbán said the company's HOPE-3 results are governed by final analysis plan SAP 3.0, finalized before unblinding, and that post-hoc analyses in the FDA package lean on SAP 1.1, an obsolete unsigned draft. The PDUFA target remains August 22. One firm cut the stock to Neutral and dropped its target to $7 from $38. The 52-week range still stretches from about $4.30 to $40.37. Here's the real fight before the July 29 panel votes. Here's What We Uncovered › Where should you invest $50 today? Sponsored Elon Musk just started backing a hot new startup that's already growing faster than Tesla… faster than SpaceX… And it's even growing 23 times faster than Nvidia. That's why The Atlantic called it… "The fastest-growing business in the history of capitalism." Even though this has nothing to do with robots, self-driving cars and rockets, its CEO is projecting growth of up to 8,000% for this year… Enough to turn $1,000 into $80,000. Click here and Jeff Brown will show you how to claim your pre-IPO stake for as little as $50. FREE REPORT Claim This Week's Free Report New to Stocks? Try This First A smart, simple strategy to build confidence and create long-term wealth. This free special report walks new investors through the first move that actually sticks. Claim This Week's Free Report › You are receiving this e-mail at fromworksmart.jewelry@blogger.com, as part of your subscription to Money Morning. Manage Your Preferences by clicking here. No longer interested? Unsubscribe. © 2026 Money Morning. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before our subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication prior to following an initial recommendation. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: First Light Financial, 1001 Cathedral St, Baltimore, MD 21201. Money Morning is a First Light Financial, LLC publication. To contact us call 866-616-2166 or visit us online. Website | Privacy Policy | Terms & Conditions